Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CAD | P27708 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3870882 | 1.00 | L3MBTL1 (0.79) | L3MBTL1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL22111187 | 1.00 | L3MBTL1 (0.79) | L3MBTL1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL30531893 | 0.89 | L3MBTL1 (0.62) | L3MBTL1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL15730803 | 0.88 | L3MBTL1 (1.00) | L3MBTL1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL4629356 | 0.87 | L3MBTL1 (0.59) | L3MBTL1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL4629355 | 0.87 | L3MBTL1 (0.59) | L3MBTL1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL31228993 | 0.87 | L3MBTL1 (0.60) | L3MBTL1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL4189292 | 0.87 | L3MBTL1 (0.84) | L3MBTL1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL4189297 | 0.87 | L3MBTL1 (0.84) | L3MBTL1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL30531875 | 0.86 | L3MBTL1 (0.59) | L3MBTL1KMT2APOLBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338643-B2 | Reagent for introduction of protein or gene | WASEDA UNIVERSITY (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20100291672-A1 | REAGENT FOR INTRODUCTION OF PROTEIN OR GENE | WASEDA UNIVERSITY (JP) | 2010-11-18 | — | — | US | disclosed |
| EP-1618117-B1 | TUMOR SELECTIVE AND BIODEGRADABLE POLYPHOSPHAZENE-PLATINUM(II) CONJUGATE ANTITUMOR AGENT, AND PREPARATION METHOD THEREOF | TRUSTEES EWHA WOMANS UNIVERSIT (KR) | 2008-04-23 | — | — | EP | disclosed |
| EP-1618117-A4 | TUMOR SELECTIVE AND BIODEGRADABLE POLYPHOSPHAZENE-PLATINUM(II) CONJUGATE ANTITUMOR AGENT, AND PREPARATION METHOD THEREOF | TRUSTEES EWHA WOMANS UNIVERSIT (KR) | 2007-04-11 | — | — | EP | disclosed |
| EP-1618117-A1 | TUMOR SELECTIVE AND BIODEGRADABLE POLYPHOSPHAZENE-PLATINUM(II) CONJUGATE ANTITUMOR AGENT, AND PREPARATION METHOD THEREOF | Board of Trustees, Ewha Womans University (KR) | 2006-01-25 | — | — | EP | disclosed |
| US-6951953-B2 | Tumor selective and biodegradable polyphosphazene-platinum(II) conjugate antitumor agent, and preparation method thereof | EWHA WOMANS UNIVERSITY (KR) | 2005-10-04 | — | — | US | disclosed |
| WO-2004096820-A1 | TUMOR SELECTIVE AND BIODEGRADABLE POLYPHOSPHAZENE-PLATINUM(II) CONJUGATE ANTITUMOR AGENT, AND PREPARATION METHOD THEREOF | BOARD OF TRUSTEES, EWHA WOMANS UNIVERSITY (KR) | 2004-11-11 | — | — | WO | disclosed |
| US-20040219127-A1 | Tumor selective and biodegradable polyphosphazene-platinum(II) conjugate antitumor agent, and preparation method thereof | EWHA WOMANS UNIVERSITY (KR) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291672-A1 | REAGENT FOR INTRODUCTION OF PROTEIN OR GENE | C1S, SGMS1, CERT1 | L3MBTL1 80/4885KMT2A 1785/4885POLB 3728/4885 |
| US-20040219127-A1 | Tumor selective and biodegradable polyphosphazene-platinum(II) conjugate antitumor agent, and preparation method thereof | PHOSPHO1, FOLR1, PCNA | L3MBTL1 1674/4885KMT2A 1444/4885POLB 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.